Dry Eye Syndrome Support Protocol

Dry eye syndrome (also called dry eye disease or keratoconjunctivitis sicca) occurs when your eyes don't produce enough tears or when the tears evaporate too quickly. Symptoms include stinging, burning, grittiness, redness, fatigue, and blurred vision. It becomes more common with age, especially in women, and can be triggered or worsened by screen use, contact lenses, certain medications, and dry environments. Dry eye has two main components: aqueous deficiency (not enough tear production) and evaporative (tears evaporate too fast, often from meibomian gland dysfunction).

IMPORTANT: Persistent dry eye symptoms should be evaluated by an eye care professional. Underlying causes (autoimmune conditions like Sjogren's syndrome, medication side effects, meibomian gland dysfunction) need proper diagnosis. Severe dry eye can damage the cornea.

•Omega-3 Fatty Acids are among the most researched supplements for dry eye. They work by reducing inflammation on the ocular surface and improving the quality of the oil layer (meibum) that prevents tear evaporation. Multiple meta-analyses show omega-3s improve dry eye symptoms and signs. Higher EPA formulations may be more effective for inflammation.

•Hyaluronic Acid Eye Drops are a mainstay of dry eye treatment. Hyaluronic acid is a natural component of tears that provides viscosity and helps tears spread evenly across the eye. It also promotes healing of the corneal surface. Available over-the-counter in various concentrations.

•Trehalose Eye Drops contain a natural sugar that protects cells from desiccation. Trehalose helps stabilize cell membranes and proteins under stress conditions. Studies show it improves comfort and ocular surface health in dry eye patients.

•Topical Vitamin A supports the health of epithelial cells on the ocular surface and promotes mucin production, which helps tears adhere to the eye. It's particularly helpful for keratinization (when the surface becomes more skin-like).

•GLA (Gamma-Linolenic Acid) from evening primrose oil or borage oil may help by providing anti-inflammatory fatty acids that support tear gland function. It's often used alongside omega-3s.

•Vitamin D deficiency has been associated with dry eye in multiple studies. While the mechanism isn't fully clear, maintaining adequate vitamin D levels may support tear function and reduce ocular surface inflammation.

•Lactoferrin is naturally present in tears and has antimicrobial and anti-inflammatory properties. Oral lactoferrin supplementation may help improve dry eye symptoms, particularly in those with low tear lactoferrin levels.

•Vitamin E as an antioxidant may help protect the delicate cells of the ocular surface from oxidative damage.

Expected timeline: Artificial tears provide immediate relief but need frequent application. Omega-3s: 6-12 weeks for full anti-inflammatory effects. Vitamin D (if deficient): 8-12 weeks. Consistency is key—dry eye management is usually long-term.

Clinical Perspective

Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film. TFOS DEWS II classification: aqueous deficient (Sjogren's and non-Sjogren's), evaporative (meibomian gland dysfunction—most common), or mixed. Pathophysiology involves tear hyperosmolarity and ocular surface inflammation creating a vicious cycle. Risk factors: age, female sex, contact lenses, screen time, medications (antihistamines, antidepressants, diuretics), autoimmune disease, refractive surgery. Diagnosis: symptom questionnaires (OSDI, SPEED), tear breakup time, Schirmer test, fluorescein staining, osmolarity testing.

CRITICAL: Rule out underlying causes—Sjogren's syndrome (sicca symptoms, joint pain, fatigue—check ANA, SSA/SSB), medication-induced, blepharitis, meibomian gland dysfunction. Treatment ladder: artificial tears, lifestyle modifications, anti-inflammatory therapy (cyclosporine, lifitegrast), punctal plugs, autologous serum. Supplements are adjunctive to standard care.

•Omega-3 Fatty Acids (B-grade): EPA/DHA reduce inflammatory mediators (PGE2, LTB4) on ocular surface. Improve meibomian gland secretion quality. Meta-analysis: omega-3s improve symptoms and signs (tear breakup time, Schirmer test) (PMID: 30899527). Systematic review confirms benefit (PMID: 29554172). 2-4g EPA+DHA daily; higher EPA may be better for inflammation. Note: DREAM study showed no benefit over placebo in moderate-severe DED—results debated; population and omega-3 formulation may matter.

•Hyaluronic Acid (Topical) (B-grade): Viscoelastic properties; promotes epithelial healing; extends tear film stability. Systematic review: HA drops improve symptoms and objective signs (PMID: 26619823). Meta-analysis: sodium hyaluronate superior to other artificial tears (PMID: 30379315). 0.1-0.2% concentration; preservative-free preferred for frequent use. Multiple formulations available OTC.

•Trehalose (Topical) (B-grade): Stabilizes cell membranes and proteins under desiccation stress; bioprotectant. Systematic review: trehalose eye drops improve symptoms and ocular surface health (PMID: 28384099). 3% concentration typical. Often combined with hyaluronic acid.

•Topical Vitamin A (B-grade): Supports goblet cell function and mucin production; promotes epithelial differentiation. Review: vitamin A beneficial for ocular surface disorders (PMID: 15741831). Particularly useful for severe dry eye with keratinization. Ointment form for overnight use; drops available.

•GLA (Gamma-Linolenic Acid) (B-grade): Precursor to anti-inflammatory prostaglandins (PGE1). Systematic review: GLA supplementation may improve dry eye symptoms (PMID: 22952697). 300-600mg GLA daily from evening primrose oil (10% GLA) or borage oil (20% GLA). Often combined with omega-3s.

•Vitamin D (C-grade): VDR in lacrimal gland and ocular surface. Multiple studies associate deficiency with DED. Systematic review: vitamin D status correlates with dry eye; supplementation may help (PMID: 28359526). Check 25(OH)D; supplement if deficient. 2000-4000 IU daily.

•Lactoferrin (C-grade): Natural tear component; antimicrobial, anti-inflammatory. Clinical trial: oral lactoferrin improved symptoms and tear stability (PMID: 22079476). 270mg daily. May particularly benefit those with low tear lactoferrin.

•Vitamin E (C-grade): Antioxidant protection for ocular surface. Review: may help as part of antioxidant approach (PMID: 20644656). 200-400 IU daily. Limited direct evidence.

Biomarker targets: Symptom scores (OSDI, SPEED), tear breakup time (>10 seconds normal), Schirmer test (>10mm normal), corneal staining score, tear osmolarity (<308 mOsm/L), meibography for gland assessment.

Protocol notes: Lifestyle modifications first: 20-20-20 rule for screen use, adequate hydration, humidifier, avoid direct airflow on eyes. Lid hygiene for blepharitis/MGD (warm compresses, lid scrubs). Preservative-free artificial tears preferred for frequent use (>4x/day). For MGD: warm compresses, omega-3s, consider in-office thermal pulsation (LipiFlow). Anti-inflammatory prescription drops (cyclosporine 0.05%, lifitegrast 5%) for moderate-severe disease. Punctal plugs for aqueous deficiency. Autologous serum tears for severe refractory cases. Address medication causes when possible. Contact lens modifications if applicable. Consider environmental factors (air travel, dry climates).

View All Protocols